Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Journal of Infectious Diseases|December 7, 2016
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya VirusAdam D DeZure, Nina M Berkowitz, Barney S Graham, et al.
The Pediatric Infectious Disease Journal|August 25, 2015
Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in ChildrenNina M Berkowitz, Michael C Spaeder, Roberta L DeBiasi, et al.
Lancet (London, England)|December 27, 2014
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trialHannah Kibuuka, Nina M Berkowitz, Monica Millard, et al.
The New England Journal of Medicine|November 27, 2014
Chimpanzee Adenovirus Vector Ebola VaccineJulie E Ledgerwood, Adam D DeZure, Daphne A Stanley, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Science (New York, N.Y.)|August 3, 2019
A proof of concept for structure-based vaccine design targeting RSV in humansMichelle C Crank, Tracy J Ruckwardt, Man Chen, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
Immunity|April 6, 2021
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesMaryam Mukhamedova, Daniel Wrapp, Chen-Hsiang Shen, et al.
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2017
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infectionKirsten E Lyke, Andrew S Ishizuka, Andrea A Berry, et al.
Pageof 2